D-Glucarate + Milk Thistle


Promotes detoxification

  • A herb and nutrient formula that protects and regenerates the liver
  • Supports liver function and protects cells from carcinogens
  • A unique formula that enhances the important detoxification process known as glucuronidation
  • Supports normal cell growth
Gluten Free

$33.06 or subscribe and save 20%

In stock

Choose a purchase plan:
If you decide a subscription is not for you, it can be cancelled after 30 days.

D-Glucarate + Milk Thistle is designed to support detoxification and overall liver health and function. It is especially helpful in the elimination of excess hormones.

D-Glucarate is a phytochemical that supports detoxification and is found naturally in many plants, including cruciferous vegetables like broccoli, cauliflower, kale and bok choy. It is also produced inside the body but only in small amounts that decrease with age. D-Glucarate supports glucuronidation, an important detoxification pathway within the body designed to eliminate potentially carcinogenic pathogens through the urine or the bile. D-Glucarate can be particularly effective in protecting hormone sensitive tissues such as the breast and prostate. Interestingly, people exposed to a toxic environment and with certain severe illnesses have been shown to have abnormally low levels of D-glucarate.

Milk thistle is an herb that has been used as a traditional remedy for over 2000 years, primarily for supporting overall liver health. Milk thistle protects the liver against toxins and supports liver function including detoxification and regeneration. Milk thistle has also been shown to inhibit the growth of abnormal cells, protect healthy cells, and protect against chemotherapy-induced liver toxicity.

D-Glucarate + Milk Thistle is an excellent addition to a detoxification program, or for anyone simply looking for a supplement to support the healthy metabolism of hormones and toxins.

AOR Advantage

AOR’s D-Glucarate + Milk Thistle is backed by extensive clinical research, attesting to the benefits of assisting the body with the detoxification process and cellular protection. In combination, these two ingredients provide optimal support to the liver and protect the cells from toxins.




D-Glucarate + Milk Thistle contains milk thistle which helps to support liver function and is used as a liver protectant. Calcium D-Glucarate is converted by the body into glucaric acid, a non-toxic compound.


AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take one capsule twice daily with food, or as directed by a qualified health care practitioner. Use for a minimum of three weeks to see beneficial effects.


Do not use if you are pregnant or breastfeeding, have a liver or eye condition, or have Sly disease. Consult a health care practitioner prior to use if you are taking other medications or antibiotics, for use beyond 28 days, or if symptoms persist or worsen. Discontinue use if hypersensitivity develops (such as an allergy) or if symptoms of liver trouble or corneal clouding develop.

Main Applications
  • Detoxification
  • Liver health
  • Healthy cellular growth

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: Two Capsules

Non-medicinal Ingredients: microcrystalline cellulose, silicon dioxide. Capsule: hypromellose.

Anti-cancer Effects of D-glucarate

Study #1:

In an animal model of lung cancer, calcium D-glucarate given as a dietary supplement to mice has been shown to suppress cell proliferation and inflammation, essentially inhibiting cancerous tumor development in mouse lungs. In a follow-up study, researchers measured inflammatory markers in a mouse model of lung cancer. They found that administering a compound (B[a]P) that increases metastatic tumor cells in the lung led to a large increases in the levels of TNF-alpha, IL-6 and IFN-g. The administration of dietary calcium d-glucarate for two weeks reduced the levels of IL-6 and TNF-alpha as well as increased levels of anti-inflammatory cytokines. The amount of stained cells in lung tissue also decreased by 35.6%. Researchers noted the proapoptotic effects of d-glucarate.

Zoltaszek R, Kowalczyk P, Kowalczyk MC, et al. (2011). Dietary D-glucarate effects on the biomarkers of inflammation during early post-initiation stages of benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Oncol Lett. 2(1): 145-54


Study #2:

In an animal model of liver cancer, rats with liver cancer were administered d-glucaro-1,4-lactone (1,4-GL) (the compound that calcium-d-glucarate is converted to in the gut after ingestion) for ten weeks. Rats with liver cancer had an increased 20-week survival rate – from 45% to 70% when treated with 1,4-GL. Additionally, treatment led to a reduction in liver carcinogenesis and significantly lower levels of alpha-fetoprotein.

Yang W, Zhou G, Zou S, et al. (2018). Metabonomic of D-glucaro-1,4-lactone in preventing diethylnitrosamine-induced liver cancer in rats. Pharmaceut Biol. 56(1): 643-8


Study #3:

Platelet activation plays a major role in tumor progression, inflammation and hemostasis. In an in-vitro study, D-glucono-1,4-lactone, sodium D-gluconate and calcium D-glucarate each individually inhibited arachidonic peroxidation induced by thrombin as well as inhibited superoxide (a free radical) production, and platelet protein oxidation.

Saluk-Juszczak J. (2010). A comparative study of antioxidative activity of calcium-D-glucarate, sodium-D-gluconate and D-glucono-1,4-lactone in a human blood platelet model. Platelets. 21(8): 632-40


Silymarin Reduces Liver Toxicity and/or Provides Liver Protection

Study #1:

In a double-blind controlled trial, patients with liver cirrhosis were randomized to either 140 mg of silymarin three times daily, or placebo for 41 months. At the end of the study, the 4-year survival rate was significantly higher in the group treated with silymarin 58 +/- 9% compared to 39 +/- 9% in the placebo group.

Ferenci P, Dragosics B, Dittrich H, et al. (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Heaptol. 9(1): 105-13


Study #2:

In a randomized placebo-controlled trial, patients with acute hepatitis and elevated ALT levels were randomized to 140mg of silymarin or a vitamin placebo for four weeks. Patients given silymarin had significantly reduced indirect bilirubin. Among the measured symptoms, patients on silymarin had significantly reduced incidences of dark urine, jaundice and scleral icterus. Researchers concluded that silymarin may be effective in improving the symptoms of acute hepatitis.

El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. (2009). A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 16(5): 391-400


Study #3:

In a double-blind, placebo-controlled clinical trial, patients with non-alcoholic fatty liver disease (NAFLD) were assigned to one of five different intervention/treatment groups, including placebo, for three months. Treatments included: 140 mg silymarin, 500mg metformin, 15 mg pioglithasone and 400IU vitamin E. Compared to placebo, the patients in all other treatment groups had significantly decreased liver enzymes (alanine transaminase and aspartate transaminase). This suggests that 140 mg of milk thistle daily is more effective than placebo at decreasing liver enzymes in patients with NAFLD and is as effective as Metformin, vitamin E and pioglithasone in doing so.

Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. (2019). Treatment options for non-alcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 31(5): 613-7